Dynamic Advisor Solutions LLC Acquires New Position in Zoetis Inc. (NYSE:ZTS)

Dynamic Advisor Solutions LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 7,613 shares of the company's stock, valued at approximately $1,253,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Norges Bank purchased a new position in Zoetis during the 4th quarter worth approximately $824,321,000. Wellington Management Group LLP raised its position in Zoetis by 78.5% during the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after buying an additional 3,059,255 shares during the last quarter. Sarasin & Partners LLP purchased a new position in Zoetis during the 1st quarter worth approximately $339,111,000. GAMMA Investing LLC raised its position in Zoetis by 14,731.3% during the 1st quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after buying an additional 1,747,423 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Zoetis during the 4th quarter worth approximately $196,651,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is owned by corporate insiders.

Zoetis Price Performance

Zoetis stock opened at $164.36 on Tuesday. The company's fifty day moving average price is $159.07 and its 200 day moving average price is $163.75. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market capitalization of $73.18 billion, a P/E ratio of 30.05, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the company earned $1.38 EPS. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis's dividend payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of recent research reports. UBS Group reduced their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Stifel Nicolaus cut their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Piper Sandler lifted their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of "Buy" and a consensus target price of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.